Data presented at ESMO Virtual Congress 2020 reported on safety profiles of some MET inhibitors when combined with tyrosine kinase inhibitors and encouraging response rates in patients with non-small-cell lung cancer with MET exon 14 skipping mutations

Studies show mixed results from combination therapies with osimertinib plus bevacizumab, and monotherapies with tarloxotinib or patritumab deruxtecan

In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients

[5:08 PM] Cinzia POZZI - ESMOchange the subtitle into: In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients

Breaking data from the IMpassion031 trial provides further evidence to support a role for immunotherapy in early-stage triple negative breast cancer (TNBC).

The ALK tyrosine kinase inhibitor lorlatinib significantly improved progression-free survival compared with crizotinib

In the Phase III trial, sacituzumab govitecan significantly improved progression-free survival and overall survival over standard chemotherapy

Results support the use of alpelisib plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer and PI3KCA mutations

Mixed results from IMpassion 130 and IMpassion 131 also draw attention to chemotherapy backbone selection 

Results from the PRODIGE 13 trial, presented at ESMO Virtual Congress 2020, show that optimisation of diagnostic procedures in terms of overall survival benefits remains to be determined

Dr Susana Banerjee summarises results from two surveys investigating the psychological impact of the pandemic on medical oncologists